Your request to link to rcsb for Bcr-Abl
- 1FPU: crystal structure of abl kinase domain in complex with a small molecule inhibitor (10.1126/SCIENCE.289.5486.1938 )
- 1IEP: crystal structure of the c-abl kinase domain in complex with sti-571.
- 1JU5: ternary complex of an crk sh2 domain, crk-derived phophopeptide, and abl sh3 domain by nmr spectroscopy (10.1073/PNAS.212518799 )
- 1K1F: structure of the bcr-abl oncoprotein oligomerization domain
- 1M52: crystal structure of the c-abl kinase domain in complex with pd173955
- 1OPJ: structural basis for the auto-inhibition of c-abl tyrosine kinase (10.1016/S0092-8674(03)00194-6 )
- 1OPK: structural basis for the auto-inhibition of c-abl tyrosine kinase (10.1016/S0092-8674(03)00194-6 )
- 1OPL: structural basis for the auto-inhibition of c-abl tyrosine kinase (10.1016/S0092-8674(03)00194-6 )
- 1ZZP: solution structure of the f-actin binding domain of bcr- abl/c-abl (10.1016/J.MOLCEL.2005.06.030 )
- 2ABL: sh3-sh2 domain fragment of human bcr-abl tyrosine kinase (10.1016/S0969-2126(96)00116-5 )
- 2E2B: crystal structure of the c-abl kinase domain in complex with inno-406 (10.1016/J.BMCL.2007.03.002 )
- 2ECD: solution structure of the human abl2 sh2 domain
- 2F4J: structure of the kinase domain of an imatinib-resistant abl mutant in complex with the aurora kinase inhibitor vx-680 (10.1158/0008-5472.CAN-05-2788 )
- 2FO0: organization of the sh3-sh2 unit in active and inactive forms of the c-abl tyrosine kinase (10.1016/J.MOLCEL.2006.01.035 )
- 2G1T: a src-like inactive conformation in the abl tyrosine kinase domain (10.1371/JOURNAL.PBIO.0040144 )
- 2G2F: a src-like inactive conformation in the abl tyrosine kinase domain (10.1371/JOURNAL.PBIO.0040144 )
- 2G2H: a src-like inactive conformation in the abl tyrosine kinase domain (10.1371/JOURNAL.PBIO.0040144 )
- 2G2I: a src-like inactive conformation in the abl tyrosine kinase domain (10.1371/JOURNAL.PBIO.0040144 )
- 2GQG: x-ray crystal structure of dasatinib (bms-354825) bound to activated abl kinase domain (10.1158/0008-5472.CAN-05-4187 )
- 2HIW: crystal structure of inactive conformation abl kinase catalytic domain complexed with type ii inhibitor (10.1016/J.CHEMBIOL.2006.05.015 )
- 2HYY: human abl kinase domain in complex with imatinib (sti571, glivec) (10.1107/S0907444906047287 )
- 2HZ0: abl kinase domain in complex with nvp-aeg082 (10.1107/S0907444906047287 )
- 2HZ4: abl kinase domain unligated and in complex with tetrahydrostaurosporine (10.1107/S0907444906047287 )
- 2HZI: abl kinase domain in complex with pd180970 (10.1107/S0907444906047287 )
- 2HZN: abl kinase domain in complex with nvp-afg210 (10.1107/S0907444906047287 )
- 2O88: crystal structure of the n114a mutant of abl-sh3 domain complexed with a designed high-affinity peptide ligand: implications for sh3-ligand interactions (10.1107/S0907444907011109 )
- 2QOH: crystal structure of abl kinase bound with ppy-a (10.1111/J.1747-0285.2007.00556.X )
- 2V7A: crystal structure of the t315i abl mutant in complex with the inhibitor pha-739358 (10.1158/0008-5472.CAN-07-1825 )
- 2XYN: human abl2 in complex with aurora kinase inhibitor vx-680 (10.1021/JM101506N )
- 2Z60: crystal structure of the t315i mutant of abl kinase bound with ppy-a (10.1111/J.1747-0285.2007.00556.X )
- 3CS9: human abl kinase in complex with nilotinib (10.1016/J.CCR.2005.01.007 )
- 3DK3: crystal structure of mutant abl kinase domain in complex with small molecule fragment
- 3DK6: crystal structure of mutant abl kinase domain in complex with small molecule fragment
- 3DK7: crystal structure of mutant abl kinase domain in complex with small molecule fragment
- 3EG0: crystal structure of the n114t mutant of abl-sh3 domain (10.1074/JBC.M109.048033 )
- 3EG1: crystal structure of the n114q mutant of abl-sh3 domain complexed with a designed high-affinity peptide ligand: implications for sh3-ligand interactions (10.1074/JBC.M109.048033 )
- 3EG2: crystal structure of the n114q mutant of abl-sh3 domain (10.1074/JBC.M109.048033 )
- 3EG3: crystal structure of the n114a mutant of abl-sh3 domain (10.1074/JBC.M109.048033 )
- 3EGU: crystal structure of the n114a mutant of abl-sh3 domain (10.1074/JBC.M109.048033 )
- 3GVU: the crystal structure of human abl2 in complex with gleevec
- 3HMI: the crystal structure of human abl2 in complex with 5-amino-3-{[4- (aminosulfonyl)phenyl]amino}-n-(2,6-difluorophenyl)-1h-1,2,4- triazole-1-carbothioamide
- 3IK3: ap24534, a pan-bcr-abl inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutation-based resistance (10.1016/J.CCR.2009.09.028 )
- 3K2M: crystal structure of monobody ha4/abl1 sh2 domain complex (10.1038/NSMB.1793 )
- 3K5V: structure of abl kinase in complex with imatinib and gnf-2 (10.1038/NATURE08675 )
- 3KF4: structural analysis of dfg-in and dfg-out dual src-abl inhibitors sharing a common vinyl purine template (10.1111/J.1747-0285.2009.00905.X )
- 3KFA: structural analysis of dfg-in and dfg-out dual src-abl inhibitors sharing a common vinyl purine template (10.1111/J.1747-0285.2009.00905.X )
- 3MS9: abl kinase in complex with imatinib and a fragment (frag1) in the myristate pocket (10.1021/JA101837N )
- 3MSS: abl kinase in complex with imatinib and fragment (frag2) in the myristate site (10.1021/JA101837N )
- 3OXZ: crystal structure of abl kinase domain bound with a dfg-out inhibitor ap24534 (10.1111/J.1747-0285.2010.01054.X )
- 3OY3: crystal structure of abl t315i mutant kinase domain bound with a dfg- out inhibitor ap24589 (10.1111/J.1747-0285.2010.01054.X )
- 3PYY: discovery and characterization of a cell-permeable, small-molecule c- abl kinase activator that binds to the myristoyl binding site (10.1016/J.CHEMBIOL.2010.12.013 )
- 3QRI: the crystal structure of human abl1 kinase domain in complex with dcc- 2036 (10.1016/J.CCR.2011.03.003 )
- 3QRJ: the crystal structure of human abl1 kinase domain t315i mutant in complex with dcc-2036 (10.1016/J.CCR.2011.03.003 )
- 3QRK: the crystal structure of human abl1 kinase domain in complex with dp- 987 (10.1016/J.CCR.2011.03.003 )
- 3T04: crystal structure of monobody 7c12/abl1 sh2 domain complex (10.1016/J.CELL.2011.08.046 )
- 3UE4: structural and spectroscopic analysis of the kinase inhibitor bosutinib binding to the abl tyrosine kinase domain (10.1371/JOURNAL.PONE.0029828 )
- 3UYO: crystal structure of monobody sh13/abl1 sh2 domain complex (10.1016/J.JMB.2011.12.019 )
- 4EIH: crystal structure of arg sh2 domain (10.1074/JBC.M114.556480 )
- 4J9B: crystal structure of the abl-sh3 domain h59q-n96t mutant
- 4J9C: crystal structure of the abl-sh3 domain h59q-n96t mutant complexed with the designed high-affinity peptide ligand p17
- 4J9D: crystal structure of the n114a mutant of the abl-sh3 domain complexed with the high affinity peptide p0
- 4J9E: crystal structure of the n114a mutant of the abl-sh3 domain complexed with the high affinity peptide p17
- 4J9F: crystal structure of the abl-sh3 domain complexed with the high affinity peptide p0
- 4J9G: crystal structure of the abl-sh3 domain complexed with the designed high-affinity peptide ligand p7 at ph7
- 4J9H: crystal structure of the abl-sh3 domain complexed with the designed high-affinity peptide ligand p7 at ph 8
- 4J9I: crystal structure of the abl-sh3 domain complexed with the designed high-affinity peptide ligand p17
- 4JJB: crystal structure of the abl-sh3 domain at ph3
- 4JJC: crystal structure of the abl-sh3 domain at ph5
- 4JJD: crystal structure of the n114a abl-sh3 domain mutant at ph4
- 4TWP: the crystal structure of human abl1 t315i gatekeeper mutant kinase domain in complex with axitinib (10.1038/NATURE14119 )
- 4WA9: the crystal structure of human abl1 wild type kinase domain in complex with axitinib (10.1038/NATURE14119 )
- 4XEY: crystal structure of an sh2-kinase domain construct of c-abl tyrosine kinase (10.1042/BJ20141492 )
- 4XLI: crystal structure of abl2/arg kinase in complex with dasatinib (10.1107/S2053230X15004793 )
- 4YC8: c-helix-out binding of dasatinib analog to c-abl kinase (10.1021/ACSCHEMBIO.5B01018 )
- 4ZOG: vx-680/mk-0457 binds to human abl1 also in inactive dfg conformations.
- 5DC0: crystal structure of monobody gg3/abl1 sh2 domain complex (10.1074/JBC.M115.707901 )
- 5DC4: crystal structure of monobody as25/abl1 sh2 domain complex, crystal a (10.1074/JBC.M115.707901 )
- 5DC9: crystal structure of monobody as25/abl1 sh2 domain complex, crystal b (10.1074/JBC.M115.707901 )
- 5HU9: crystal structure of abl1 in complex with chmfl-074 (10.18632/ONCOTARGET.10037 )
- 5MO4: abl1 kinase (t334i_d382n) in complex with asciminib and nilotinib (10.1038/NATURE21702 )
- 5N6R: solution structure of the dbl-homology domain of bcr-abl (10.1038/S41467-017-02313-6 )
- 5N7E: crystal structure of the dbl-homology domain of bcr-abl in complex with monobody mb(bcr-dh_4). (10.1038/S41467-017-02313-6 )
- 5NP2: abl1 sh3 ptyr89/134 (10.1074/JBC.RA118.004732 )
- 5NP3: abl2 sh3 (10.1074/JBC.RA118.004732 )
- 5NP5: abl2 sh3 ptyr116/161 (10.1074/JBC.RA118.004732 )
- 5OAZ: crystal structure of the abl-sh3 domain at ph 7.5
- 5OC7: crystal structure of the pleckstrin-homology domain of bcr-abl in complex with monobody mb(bcr-ph_4). (10.1038/S41467-017-02313-6 )
- 6AMV: abl 1b regulatory module 'inhibiting state' (10.1038/NSMB.3470 )
- 6AMW: abl1b regulatory module 'activating' conformation (10.1038/NSMB.3470 )
- 6BL8: predicting the conformational variability of abl tyrosine kinase using molecular dynamics simulations and markov state models (10.1021/ACS.JCTC.7B01170 )
- 6HD4: abl1 in complex with compound 7 and imatinib (sti-571) (10.1021/ACS.JMEDCHEM.8B01040 )
- 6HD6: abl1 in complex with compound6 and imatinib (sti-571) (10.1021/ACS.JMEDCHEM.8B01040 )
- 6NPE: c-abl kinase domain with the activator(cmpd6), 2-cyano-n-(4-(3,4- dichlorophenyl)thiazol-2-yl)acetamide (10.1021/ACS.JMEDCHEM.8B01872 )
- 6NPU: c-abl kinase domain with the activator(cmpd29), n-(1-(3,4- dichlorophenyl)-4,5-dihydro-1h-pyrazol-3-yl)acetamide (10.1021/ACS.JMEDCHEM.8B01872 )
- 6NPV: c-abl kinase domain with the activator(cmpd51), n-(1-(3,4- dichlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1h-pyrazol-3-yl) isonicotinamide (10.1021/ACS.JMEDCHEM.8B01872 )
- 6XR6: abl 1b isoform active state (10.1126/SCIENCE.ABC2754 )
- 6XR7: abl isoform 1b inactive1 state (10.1126/SCIENCE.ABC2754 )
- 6XRG: abl 1b isoform inactive2 state (10.1126/SCIENCE.ABC2754 )
- 7CC2: strategic design of catalytic lysine-targeting reversible covalent bcr-abl inhibitors (10.1002/ANIE.202105383 )
- 7DT2: strategic design of catalytic lysine-targeting reversible covalent bcr-abl inhibitors (10.1002/ANIE.202105383 )